Status:
RECRUITING
Registry Study of Chinese Patients with Marginal Zone Lymphoma (MOTIVE)
Lead Sponsor:
Ruijin Hospital
Conditions:
Marginal Zone Lymphoma
Eligibility:
All Genders
14+ years
Brief Summary
This study aims to evaluate real-world treatment modalities and their corresponding effectiveness and safety in Chinese patients with marginal zone lymphoma, while also exploratively analyzing patient...
Eligibility Criteria
Inclusion
- Be diagnosed as MZL
- Meet the treatment indications for MZL
Exclusion
- Any reason that, in the investigator's opinion, makes the participant unsuitable to participate in this study.
Key Trial Info
Start Date :
August 2 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 1 2029
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT06534463
Start Date
August 2 2024
End Date
September 1 2029
Last Update
December 3 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shanghai Ruijin Hospital
Shanghai, Shanghai Municipality, China, 200025